KR20220074913A - S1p1 수용체와 관련된 상태를 치료하는 방법 - Google Patents

S1p1 수용체와 관련된 상태를 치료하는 방법 Download PDF

Info

Publication number
KR20220074913A
KR20220074913A KR1020227014194A KR20227014194A KR20220074913A KR 20220074913 A KR20220074913 A KR 20220074913A KR 1020227014194 A KR1020227014194 A KR 1020227014194A KR 20227014194 A KR20227014194 A KR 20227014194A KR 20220074913 A KR20220074913 A KR 20220074913A
Authority
KR
South Korea
Prior art keywords
compound
disease
administered
treatment
induction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020227014194A
Other languages
English (en)
Korean (ko)
Inventor
타이 커티스 응웬-클리어리
리젯 마리 에이스베도
Original Assignee
아레나 파마슈티칼스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아레나 파마슈티칼스, 인크. filed Critical 아레나 파마슈티칼스, 인크.
Publication of KR20220074913A publication Critical patent/KR20220074913A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227014194A 2019-10-01 2020-09-30 S1p1 수용체와 관련된 상태를 치료하는 방법 Withdrawn KR20220074913A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962909113P 2019-10-01 2019-10-01
US62/909,113 2019-10-01
PCT/US2020/053642 WO2021067506A1 (en) 2019-10-01 2020-09-30 Methods of treating conditions related to the s1p1 receptor

Publications (1)

Publication Number Publication Date
KR20220074913A true KR20220074913A (ko) 2022-06-03

Family

ID=75337529

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227014194A Withdrawn KR20220074913A (ko) 2019-10-01 2020-09-30 S1p1 수용체와 관련된 상태를 치료하는 방법

Country Status (12)

Country Link
US (1) US20220347158A1 (https=)
EP (1) EP4037678A4 (https=)
JP (1) JP2022550458A (https=)
KR (1) KR20220074913A (https=)
CN (2) CN115038438A (https=)
AU (1) AU2020360413A1 (https=)
BR (1) BR112022005999A2 (https=)
CA (1) CA3156182A1 (https=)
IL (1) IL291654A (https=)
MX (1) MX2022003982A (https=)
TW (1) TW202114656A (https=)
WO (1) WO2021067506A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240134360A (ko) 2022-01-13 2024-09-09 아레나 파마슈티칼스, 인크. 호르몬 치료와 조합되어 s1p1 수용체-연관된 장애를 치료하는 데 사용하기 위한 에트라시모드

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580841B2 (en) * 2008-07-23 2013-11-12 Arena Pharmaceuticals, Inc. Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
JP5856980B2 (ja) * 2010-01-27 2016-02-10 アリーナ ファーマシューティカルズ， インコーポレイテッド （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス
PL3242666T3 (pl) * 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
BR112017027656B1 (pt) * 2015-06-22 2023-12-05 Arena Pharmaceuticals, Inc. Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
MX2019009843A (es) * 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales.

Also Published As

Publication number Publication date
AU2020360413A8 (en) 2022-04-21
WO2021067506A1 (en) 2021-04-08
IL291654A (en) 2022-05-01
BR112022005999A2 (pt) 2022-07-12
US20220347158A1 (en) 2022-11-03
TW202114656A (zh) 2021-04-16
CN119280227A (zh) 2025-01-10
CN115038438A (zh) 2022-09-09
EP4037678A1 (en) 2022-08-10
EP4037678A4 (en) 2023-11-29
CA3156182A1 (en) 2021-04-08
JP2022550458A (ja) 2022-12-01
AU2020360413A1 (en) 2022-04-14
MX2022003982A (es) 2022-07-12

Similar Documents

Publication Publication Date Title
EP3908276B1 (en) Methods of treating conditions related to the s1p1 receptor
JP6580053B2 (ja) 潰瘍性大腸炎の治療用医薬組成物
JP2017200926A (ja) 第一選択の抗ＴＮＥα療法に失敗したクローン病患者を治療するためのラキニモドの使用
JP2022536623A (ja) 肺動脈性肺高血圧症の治療方法
JP2022511788A (ja) Ｓ１ｐ１受容体に関連する状態を治療する方法
WO2022099150A1 (en) Methods of treating conditions related to the s1p1 receptor
KR20220074913A (ko) S1p1 수용체와 관련된 상태를 치료하는 방법
US20240299318A1 (en) Amiselimod for preventing, treating or ameliorating ulcerative colitis
RU2821032C1 (ru) Способы лечения заболеваний, связанных с рецептором s1p1
TWI855501B (zh) 治療方法
HK40063670A (en) Methods of treating conditions related to the s1p1 receptor
HK40063670B (en) Methods of treating conditions related to the s1p1 receptor
KR102958419B1 (ko) S1p₁ 수용체와 관련된 병태의 치료 방법
WO2025134072A1 (en) Methods for preventing, treating, or ameliorating ulcerative colitis in certain patient populations with amiselimod
HK40116740A (zh) 治疗与s1p1受体有关的病况的方法
WO2023214312A1 (en) Methods of treating atopic dermatitis with etrasimod
HK40109901A (zh) 与激素治疗组合的用於治疗s1p1受体相关病症的伊曲莫德
AU2023203085A1 (en) Methods of treating conditions related to the S1P1 receptor
HK40094222A (zh) 预防、治疗或改善溃疡性结肠炎的阿米莫德

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202